πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

314 results for β€œcells” Clear

  1. Follicle Stimulating Hormone Receptor T Cells

    Anixa Biosciences Inc

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  2. GPC3 and/or TGFΞ² targeting CAR-T cells

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  3. GPC3-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 mab on hold

    1 trial

  4. Human Amniotic Epithelial Stem Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  5. Human BCMA targeted T Cells Injection

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  6. Human Umbilical Mesenchymal Stem Cells

    The First People's Hospital of Lianyungang

    Osteoarthritis, Knee

    phase 1 mab active

    1 trial

  7. Human amniotic epithelial stem cells（hAESCsοΌ‰

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Graft Versus Host Disease

    phase 1 mab terminated

    1 trial

  8. Human amniotic-derived mesenchymal stem cells

    The First People's Hospital of Lianyungang

    Chronic Kidney Diseases

    phase 1 mab active

    1 trial

  9. Human umbilical cord mesenchymal stem cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pneumoconiosis

    phase 1 mab active

    1 trial

  10. Interleukin, NK cells

    Hospital Authority, Hong Kong

    Metastatic Nasopharyngeal

    phase 1 small molecule completed

    1 trial

  11. JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)

    Shanghai University of Traditional Chinese Medicine

    Diffuse Large B Cell Lymphoma

    phase 1 mab completed

    1 trial

  12. KK-LC-1 TCR-T cells

    Iovance Biotherapeutics B.V.

    Gastric Cancer

    phase 1 mab active

    1 trial

  13. KSH01 injection

    TScan Therapeutics

    TCR-T Cells

    phase 1 small molecule active

    1 trial

  14. KSX01-TCRT injection

    TScan Therapeutics

    TCR-T Cells

    phase 1 small molecule active

    1 trial

  15. KYV-101 (Biological) - 0.33 Γ—10^8 cells

    Kyverna Therapeutics

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

  16. LCAR-AIO Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphocytic Leukemia

    phase 1 mab terminated

    1 trial

  17. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Multiple Sclerosis (MS)

    phase 1 mab active

    1 trial

  18. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab terminated

    1 trial

  19. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  20. LCAR-AIO cells product

    Nanjing Legend Biotech Co.

    B-cell Lymphoma Recurrent

    phase 1 mab terminated

    1 trial

  21. LCAR-AMDR Cells Product

    Nanjing Legend Biotech Co.

    Acute Myeloid Leukemia

    phase 1 mab terminated

    1 trial

  22. LCAR-BCDR cells product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab terminated

    1 trial

  23. LCAR-BCX cells product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab active

    1 trial

  24. LCAR-C182A cells

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources